Drug Trial Radar · NCT06251180
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Jun 30, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.Industry
- Sponsor type
- Industry
- First posted
- Feb 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma \[Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)\].
Conditions
- B-cell Non-Hodgkin Lymphoma
Interventions
RocbrutinibDrug
orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
RituximabBiological
375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
CyclophosphamideDrug
750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
doxorubicinDrug
50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
VincristinDrug
1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
PrednisoneDrug
100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: Up to 21 days after the initial dose
- Recommended DoseTime frame: Up to 1.5 years
- Incidence of AEsTime frame: From first dose of study drug to 28 days after the last dose of study drugs
- Incidence of clinically significant laboratory abnormalitiesTime frame: From first dose of study drug to 28 days after last dose of study drug
- Cmax of RocbrutinibTime frame: Up to 24 hours post dose
- Tmax of RocbrutinibTime frame: Up to 24 hours post dose
- T1/2 of RocbrutinibTime frame: Up to 24 hours post dose
- AUC0-t of RocbrutinibTime frame: Up to 24 hours post dose
- CL/F of RocbrutinibTime frame: Up to 24 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.